至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

A membrane-delimited N-myristoylated CRMP2 peptide aptamer inhibits CaV2.2 trafficking and reverses inflammatory and postoperative pain behaviors.

Pain. 2015; 
François-MoutalLiberty,WangYue,MoutalAubin,CottierKarissa E,MelemedjianOhannes K,YangXiaofang,WangYuying,JuWeina,Largent-MilnesTally M,KhannaMay,VanderahTodd W,KhannaRa
Products/Services Used Details Operation
Peptide Synthesis … The following peptides were synthesized and HPLC purified by GenScript USA Inc (Piscataway, NJ): N-terminal myristoylated peptide (myr-tat-CBD3; N-myristoyl-YGRKKRRQRRRA RSRLAELRGVPRGL; tat sequence denoted in the underlined text), a nonmyristoylated … Get A Quote

摘要

Targeting proteins within the N-type voltage-gated calcium channel (CaV2.2) complex has proven to be an effective strategy for developing novel pain therapeutics. We describe a novel peptide aptamer derived from the collapsin response mediator protein 2 (CRMP2), a CaV2.2-regulatory protein. Addition of a 14-carbon myristate group to the peptide (myr-tat-CBD3) tethered it to the membrane of primary sensory neurons near surface CaV2.2. Pull-down studies demonstrated that myr-tat-CBD3 peptide interfered with the CRMP2-CaV2.2 interaction. Quantitative confocal immunofluorescence revealed a pronounced reduction of CaV2.2 trafficking after myr-tat-CBD3 treatment and increased efficiency in disrupting CRMP2-CaV2.2 c... More

关键词